Current Report Filing (8-k)
October 05 2020 - 05:17PM
Edgar (US Regulatory)
0001425205 false 0001425205 2020-10-05
2020-10-05 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
Current Report
Pursuant to Section 13 or 15(d) of the Securities Exchange Act
of 1934
Date of Report (date of earliest event reported):
October 5, 2020
IOVANCE BIOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware |
(State of Incorporation) |
|
001-36860 |
|
75-3254381 |
Commission File Number |
|
(I.R.S. Employer Identification No.) |
|
|
|
999 Skyway Road,
Suite 150 |
|
|
San Carlos,
California |
|
94070 |
(Address of Principal Executive Offices) |
|
(Zip Code) |
|
|
|
(650)
260-7120 |
(Registrant’s Telephone Number, Including Area Code) |
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
¨ |
Written communications pursuant to
Rule 425 under the Securities Act
(17 CFR 230.425). |
|
¨ |
Soliciting material pursuant to
Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12). |
|
¨ |
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b)). |
|
¨ |
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c)). |
Indicate
by check mark whether the registrant is an emerging growth company
as defined in as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter). Emerging growth
company
¨
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ¨
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common stock, par value $0.000041666 per value |
IOVA |
The Nasdaq Stock Market, LLC |
On October 5, 2020, Iovance Biotherapeutics, Inc. (the “Company”)
updated its corporate presentation that it uses for presentations
at healthcare conferences and to analysts, current stockholders,
and others. A copy of the Company’s presentation that it intends to
use at such events is attached as Exhibit 99.1 and incorporated
herein by reference.
On October 5, 2020, the Company issued a press release providing a
regulatory update for its tumor-infiltrating lymphocyte therapy
lifileucel in metastatic melanoma. The full text of the press
release is attached hereto as Exhibit 99.2 and incorporated herein
by reference.
|
Item 9.01 |
Financial Statements and Exhibits. |
(d) Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the Registrant has duly caused this Report to be signed on
its behalf by the undersigned hereunto duly authorized.
Date:
October 5, 2020 |
IOVANCE
BIOTHERAPEUTICS, INC. |
|
|
|
|
|
|
|
|
|
By: |
/s/ MARIA
FARDIS |
|
|
|
Maria
Fardis, Chief Executive Officer |
|